1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir

      ,

      Therapeutics and Clinical Risk Management

      Dove Medical Press

      darunavir, protease inhibitors, treatment, child, adolescent

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Darunavir is currently the most recently approved HIV-1 protease inhibitor. It is approved for twice-daily dosing with ritonavir in treatment-experienced patients as young as 6 years of age and is available in numerous pill strengths. Emergence of darunavir-specific mutations is generally slow; therefore it can retain activity against viral strains that are resistant to other protease inhibitors, including tipranavir. Darunavir pharmacokinetics, clinical efficacy, resistance mutations and pharmacodynamics, and adverse effects are reviewed here. Substantial data support its use as a potent, well-tolerated option for salvage therapy in highly treatment-experienced children and adolescents.

          Related collections

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          2009
          2009
          3 August 2009
          : 5
          : 595-615
          Affiliations
          University of Southern California, Keck School of Medicine, Department of Pediatrics, Division of infectious Diseases, Los Angeles, CA, USA
          Author notes
          Correspondence: Michael Neely, 1640 Marengo St., Suite 300, Los Angeles, CA 90033, USA, Tel +1 (323) 226-2330, Fax +1 (323) 226-2505, Email mneely@ 123456usc.edu
          Article
          tcrm-5-595
          2724190
          19707276
          © 2009 Neely and Kovacs, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Medicine

          protease inhibitors, child, treatment, adolescent, darunavir

          Comments

          Comment on this article